A growing body of pharmacological research is examining natural compounds for supportive roles in oncology care. While none replace conventional cancer therapy, several show preclinical and early clinical signals worth understanding within an integrative framework โ particularly when sourced and manufactured to German pharmaceutical standards.
Cordyceps mushroom โ specifically Cordyceps militaris standardised for cordycepin content โ has been studied for effects on tumour cell proliferation pathways and immune modulation. Multiple in-vitro studies and animal models suggest cordycepin may interact with adenosine receptors and modulate cell cycle proteins in transformed cells.
Curcumin (the active polyphenol in turmeric) has been one of the most extensively researched natural compounds in oncology, but standard turmeric has near-zero bioavailability. Modern liposomal and phytosome formulations achieve plasma levels relevant for in-vivo pharmacology. Research has examined curcumin's effects on NF-ฮบB, COX-2 and apoptotic pathways across many cancer cell lines.
Khavinson peptide bioregulators occupy a different niche โ primarily supportive of organ function during and after conventional treatment. Vladonix and Crystagen support thymic immune competence; Vesugen supports vascular health; tissue-specific peptides may help organ recovery between treatment cycles.
PeptideComb manufactures and sources these compounds in Germany under pharmaceutical-grade GMP conditions. All applications in active oncology must be coordinated with the treating physician โ these compounds are supportive tools, not primary therapy.
